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ABSTRACT
High flow nasal cannula oxygen therapy (HFNC) has become frequent in the treatment 
of patients with acute hypoxemic respiratory failure. Methods. Eleven patients with 
acute exacerbation of fibrotic interstitial lung disease (ILD) were treated with HFNC after 
failure of conventional therapy (SatO2 < 90% offering 100% FiO2 by non-rebreathing 
mask or noninvasive ventilation). Ten patients had success with HFNC (not requiring 
orotracheal intubation) during emergency department admission. HFNC significantly 
improves clinical variables after 2h: respiratory rate decreased from 33 ± 6 breaths/
min to 23 ± 3 breaths/min; PaO2 increased from 48.7 (38-59) mmHg to 81.1 (76-90) 
mmHg; PaO2/FiO2 ratio increased from 102.4 ± 32.2 to 136.6 ± 29.4; SatO2 increased 
from 85 (66-92)% to 96 ± (95-97)%. HFNC could be an effective alternative in the 
treatment of acute respiratory failure from acute exacerbations of fibrotic ILD.
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Fibrotic interstitial lung diseases (ILDs) represent a pathologically 
heterogeneous group of diseases in which impaired tissue oxygen delivery 
occurs. ILDs involve interstitial pulmonary histologic abnormalities that lead 
to profound impairment of lung physiology and function. Gas exchange is 
impaired secondary to V/Q mismatching, shunting, and decreased diffusion 
across the abnormal interstitium1. Acute exacerbation of fibrotic ILD is a 
leading cause of death, often complicated by severe hypoxemia2,3.
Noninvasive ventilation (NIV) has been a viable option as it results in 
better patient survival and lower high-care unit use4. However, the increased 
work of breathing due to decreased lung compliance may be an important 
factor for poor NIV tolerance in these patients during acute exacerbations5. 
High-flow nasal cannula oxygen therapy (HFNC) provides an alternative 
to conventional oxygen therapy whereby heated and humidified oxygen is 
delivered to the nose at high flow rates and the fraction of inspired oxygen 
(FiO2) can be adjusted by changing the fraction of oxygen in the driving 
gas6-9. HFNC has been commonly used in the treatment of patients with acute 
hypoxemic respiratory failure as it results in greater comfort and oxygenation 
than standard oxygen therapy delivered through a face mask, also helping 
decrease the work of breathing6.
HFNC might potentially be an alternative to conventional oxygen therapy 
in patients requiring both high flows and high oxygen concentrations, such 
as patients with acute exacerbation of fibrotic ILD, to correct hypoxemia 
and control dyspnea; however, evidence is still scarce7. In this prospective 
analysis, we assessed short-term effects (need for endotracheal intubation, 
clinical outcomes, arterial blood gases, and length of hospital stay) in patients 
with acute respiratory failure due to acute exacerbation of fibrotic ILD in the 
emergency department (ED).
METHODS
We enrolled 11 patients with acute respiratory failure due to acute 
exacerbation of fibrotic ILD diagnosed by clinical, physiological, and high-
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resolution computed tomography criteria. This study 
was conducted in the ED of a university hospital 
between December 2016 and October 2017. The 
primary outcome was the proportion of patients 
who required endotracheal intubation despite HFNC 
therapy, and secondary outcomes were arterial blood 
gases, Borg scale, and improvement in vital signs. 
The study was approved by the Institutional Ethics 
Committee of our hospital and patients consented 
to participate.
All patients were treated with HFNC after failure 
of conventional therapy, defined as arterial oxygen 
saturation (SaO2) < 90% with non-rebreathing mask 
and/or NIV or if conventional therapy was not tolerated.
HFNC was delivered using an Optiflow nasal 
interface and circuit connected to a heated humidifier 
(MR730; Fisher & Paykel Healthcare, Auckland, New 
Zealand) with flow generated through a mechanical 
ventilator with oxygen therapy software (EVITA XL, 
Dräger, Lübeck, Germany). This system delivers 
oxygen at a maximum flow of 50 L/min. Data were 
collected before and 2 hours after HFNC and included 
respiratory rate (RR), heart rate (HR), arterial oxygen 
saturation by pulse oximetry (SpO2), arterial blood 
gases as arterial partial pressure of oxygen (PaO2), 
arterial partial pressure of carbon dioxide (PaCO2), 
ratio of PaO2 to the fraction of inspired oxygen (FiO2), 
and subjective dyspnea (Borg scale, 0 = no dyspnea 
to 10 = maximum dyspnea).
Need for intubation was defined as RR > 40 breaths/
min, signs of high respiratory muscle workload, and 
SpO2 < 90% with FiO2 1.0.
HFNC was started in all patients with the flow 
set at 50 L/min and FiO2 to maintain SpO2 > 90% 
and according to the patient’s comfort and vital 
signs. Weaning started after improvement of the 
patient’s initial condition with reduction of FiO2 up 
to 40% and flow in steps of 5 L/min until reaching 
15 L/min.
Data are expressed in mean and standard 
deviation and median and interquartile range (25th-
75th percentiles). The Shapiro-Wilk test was used 
to determine the normality of data distribution of the 
variables, and those with normal distribution were 
compared by the t-test. The level of significance was 
set at p ≤ 0.05.
RESULTS
Eleven patients (7 women) were included in 
the study (Table 1). The mean hospital stay was 
17.1 ± 8.4 days, and total in-hospital mortality was 
54%. Patients’ vital signs and arterial blood gases 
improved (Figure 1). One patient (9.1%) required 
orotracheal intubation in the ED for increased 
ventilatory effort and desaturation even after the 
start of HFNC therapy.
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Figure 1: Changes in pH (A), RR (B), PaCO2 (C), PaO2/FiO2 ratio (D), SpO2 (E) and dyspnea (F) before and after 
2 hours high flow nasal cannula (HFNC). Lines represent median +/- standard error. *P < 0.01 comparing before and 
after HFNC. PCO2, arterial carbon dioxide pressure; PaO2, arterial oxygen pressure; FiO2, inspired oxygen fraction; 
SpO2, pulse oximetry; subjective dyspnea scale Borg.
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Table 1: Baseline characteristics of patients
Characteristic Result
Age, mean ± SD (yr) 63 ± 8.6
Women , No. (%) 7 (63.6)
BMI, mean ± SD (kg/m2) 27.2 ± 4.1
TLC, % of predicted 59 ± 8.8
FVC, % of predicted 48 ± 9.8
Comorbidities, No. (%)
Arterial hypertension 3 (27)
Diabetes mellitus 3 (27)
COPD 1 (9)
Asthma 1 (9)
Heart failure 1 (9)
Previous use of home oxygen, No. (%) 2 (18)
SD: standard deviation. BMI: body mass index. TLC: total lung capacity. FVC: forced vital capacity. COPD: chronic obstructive pulmonary disease.
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